NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?

NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?

Melanie Senior

For proof of how the biopharmaceutical world is changing, look no further than NicOx SA. Shares in this French biotech...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo